Here is the clinical profile for Buprenorphine Tablet (Sublingual) 0.4 mg โ without brand names and in professional format:
๐ Buprenorphine Sublingual Tablet 0.4 mg
โ DESCRIPTION
Buprenorphine is a partial opioid agonist, primarily used for pain management and opioid dependence treatment. The 0.4 mg sublingual tablet is a low-dose formulation used for mild pain or the initiation phase of opioid substitution therapy.
๐งช FORMULATION
- Active Ingredient: Buprenorphine Hydrochloride
- Strength: 0.4 mg
- Form: Sublingual tablet
- Route of Administration: Sublingual (under the tongue)
๐ฟ NATURE
- Class: Partial opioid agonist (ยต-receptor) and antagonist (ฮบ-receptor)
- Mechanism of Action: Binds to opioid receptors in the CNS, producing analgesia and suppressing withdrawal
- Potency: ~25โ50 times stronger than morphine on a per mg basis
- Duration: Long-acting due to high receptor affinity
๐ USES
Approved Uses:
- Moderate to severe pain (acute or chronic)
- Opioid withdrawal management
- Opioid substitution therapy (OST) โ usually in combination with other strengths/formulations
Off-label:
- Neuropathic pain
- Cancer pain (in opioid-tolerant patients)
- Step-down detox in opioid-dependent individuals
๐ ADVANTAGES
- Ceiling effect for respiratory depression (safer than full agonists)
- Lower risk of overdose at this dose
- Useful in both pain and de-addiction management
- Long half-life allows less frequent dosing
- Lower abuse potential compared to full agonists
โ ๏ธ PRECAUTIONS
Common Side Effects:
- Drowsiness, dizziness
- Constipation
- Dry mouth
- Nausea or vomiting
- Headache
Serious Risks:
- Respiratory depression (especially when combined with other CNS depressants)
- Withdrawal in opioid-dependent individuals if used improperly
- Hypotension, bradycardia
- Liver enzyme elevation
โ CONTRAINDICATIONS
- Hypersensitivity to buprenorphine
- Severe respiratory insufficiency
- Acute intoxication with alcohol, sedatives, or other opioids
- Paralytic ileus
๐ฉโโ๏ธ USE IN SPECIAL POPULATIONS
- Pregnancy: Use only if clearly needed โ may cause neonatal withdrawal
- Lactation: Secreted in breast milk; caution advised
- Elderly: Increased sensitivity possible
- Children: Use not established below 16 years
๐ INTERACTIONS
- Benzodiazepines, alcohol, barbiturates โ Increased CNS/respiratory depression risk
- Other opioids โ Risk of withdrawal (due to receptor blocking)
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) โ May increase buprenorphine levels
- CYP3A4 inducers โ May reduce effectiveness
๐ก ADMINISTRATION ADVICE
- Place the tablet under the tongue and allow it to dissolve completely
- Do not chew, swallow, or crush
- Avoid eating or drinking until fully dissolved (~5โ10 mins)
- Must be administered under medical supervision for opioid dependence
- Monitor closely during initiation and dose adjustments
๐ง STORAGE
- Store at 20โ25ยฐC (68โ77ยฐF)
- Protect from light and moisture
- Keep out of reach of children (risk of accidental overdose)
- Controlled substance โ secure storage required